Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
- Author
- KELLEY, R. K1 ; NIMEIRI, H. S2 ; LUTTGEN, M. S5 ; GRABOWSKY, J. A1 ; STUCKY-MARSHALL, L2 ; KORN, W. M1 ; KO, A. H1 ; BERGSLAND, E. K1 ; BENSON, A. B2 ; VENOOK, A. P1 ; MUNSTER, P. N1 ; VERGO, M. T2 ; HUANG, Y3 ; LI, C.-M3 ; HWANG, J1 ; MULCAHY, M. F2 ; YEH, B. M4 ; KUHN, P5
[1] Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, United States
[2] Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, United States
[3] Drug Studies Unit, Department of Bioengineering & Therapeutic Sciences, UCSF, San Francisco, United States
[4] Department of Radiology, UCSF, San Francisco, United States
[5] Department of Cell Biology, The Scripps Research Institute, La Jolla, United States - Source
Annals of oncology. 2013, Vol 24, Num 7, pp 1900-1907, 8 p ; ref : 45 ref
- ISSN
- 0923-7534
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Oxford University Press, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- hepatocellular carcinoma mTOR pharmacokinetics sorafenib temsirolimus
- Keyword (fr)
- Antiangiogénique Anticancéreux Cancer du foie Carcinome hépatocellulaire Dose Essai clinique Marqueur biologique Pharmacocinétique Protéine mTOR Sorafénib Temsirolimus Inhibiteur mTOR Cancer Inhibiteur de la tyrosine kinase Inhibiteur enzyme Inhibiteur multikinase Pathologie de l'appareil digestif Pathologie du foie Tumeur maligne
- Keyword (en)
- Antiangiogenic agent Antineoplastic agent Liver cancer Hepatocellular carcinoma Dose Clinical trial Biological marker Pharmacokinetics Mammalian target of rapamycin Sorafenib Temsirolimus Cancer Tyrosine kinase inhibitor Enzyme inhibitor Multikinase inhibitor Digestive diseases Hepatic disease Malignant tumor
- Keyword (es)
- Antiangiogenico Anticanceroso Cáncer del hígado Carcinoma hepatocelular Dosis Ensayo clínico Marcador biológico Farmacocinética Proteína mTOR Sorafenib Temsirolimus Cáncer Inhibidor tyrosine kinase Inhibidor enzima inhibidor multicinasa Aparato digestivo patología Hígado patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13C Liver. Biliary tract. Portal circulation. Exocrine pancreas / 002B13C01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Pharmacological treatments Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27480879
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1093/annonc/mdt109 
https://dx.doi.org/10.1093/annonc/mdt109
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdt109\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1900\";s:8:\"\u0000*\u0000epage\";s:4:\"1907\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KELLEY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:13:\"NIMEIRI, H. S\";i:1;s:13:\"LUTTGEN, M. S\";i:2;s:15:\"GRABOWSKY, J. A\";i:3;s:18:\"STUCKY-MARSHALL, L\";i:4;s:10:\"KORN, W. M\";i:5;s:8:\"KO, A. H\";i:6;s:15:\"BERGSLAND, E. K\";i:7;s:12:\"BENSON, A. B\";i:8;s:12:\"VENOOK, A. P\";i:9;s:13:\"MUNSTER, P. N\";i:10;s:11:\"VERGO, M. T\";i:11;s:8:\"HUANG, Y\";i:12;s:8:\"LI, C.-M\";i:13;s:8:\"HWANG, J\";i:14;s:13:\"MULCAHY, M. F\";i:15;s:9:\"YEH, B. M\";i:16;s:7:\"KUHN, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdt109\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1900\";s:8:\"\u0000*\u0000epage\";s:4:\"1907\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KELLEY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:13:\"NIMEIRI, H. S\";i:1;s:13:\"LUTTGEN, M. S\";i:2;s:15:\"GRABOWSKY, J. A\";i:3;s:18:\"STUCKY-MARSHALL, L\";i:4;s:10:\"KORN, W. M\";i:5;s:8:\"KO, A. H\";i:6;s:15:\"BERGSLAND, E. K\";i:7;s:12:\"BENSON, A. B\";i:8;s:12:\"VENOOK, A. P\";i:9;s:13:\"MUNSTER, P. N\";i:10;s:11:\"VERGO, M. T\";i:11;s:8:\"HUANG, Y\";i:12;s:8:\"LI, C.-M\";i:13;s:8:\"HWANG, J\";i:14;s:13:\"MULCAHY, M. F\";i:15;s:9:\"YEH, B. M\";i:16;s:7:\"KUHN, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdt109\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdt109\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1900\";s:8:\"\u0000*\u0000epage\";s:4:\"1907\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KELLEY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:13:\"NIMEIRI, H. S\";i:1;s:13:\"LUTTGEN, M. S\";i:2;s:15:\"GRABOWSKY, J. A\";i:3;s:18:\"STUCKY-MARSHALL, L\";i:4;s:10:\"KORN, W. M\";i:5;s:8:\"KO, A. H\";i:6;s:15:\"BERGSLAND, E. K\";i:7;s:12:\"BENSON, A. B\";i:8;s:12:\"VENOOK, A. P\";i:9;s:13:\"MUNSTER, P. N\";i:10;s:11:\"VERGO, M. T\";i:11;s:8:\"HUANG, Y\";i:12;s:8:\"LI, C.-M\";i:13;s:8:\"HWANG, J\";i:14;s:13:\"MULCAHY, M. F\";i:15;s:9:\"YEH, B. M\";i:16;s:7:\"KUHN, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdt109\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"24\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1900\";s:8:\"\u0000*\u0000epage\";s:4:\"1907\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KELLEY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. K\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:13:\"NIMEIRI, H. S\";i:1;s:13:\"LUTTGEN, M. S\";i:2;s:15:\"GRABOWSKY, J. A\";i:3;s:18:\"STUCKY-MARSHALL, L\";i:4;s:10:\"KORN, W. M\";i:5;s:8:\"KO, A. H\";i:6;s:15:\"BERGSLAND, E. K\";i:7;s:12:\"BENSON, A. B\";i:8;s:12:\"VENOOK, A. P\";i:9;s:13:\"MUNSTER, P. N\";i:10;s:11:\"VERGO, M. T\";i:11;s:8:\"HUANG, Y\";i:12;s:8:\"LI, C.-M\";i:13;s:8:\"HWANG, J\";i:14;s:13:\"MULCAHY, M. F\";i:15;s:9:\"YEH, B. M\";i:16;s:7:\"KUHN, P\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
